How many employees does Denali Therapeutics Inc. have?

Denali Therapeutics Inc. reported 445 employees for the fiscal year ending Dec 2023, in the annual report it filed on February 28, 2024. That is up 4.2% from a year earlier.

What is Denali Therapeutics Inc.'s revenue per employee?

Denali Therapeutics Inc. brought in $331M of revenue in fiscal Dec 2023, which is $743K per employee. That ranks 41 of 109 companies we track in Biotechnology, where the median is $459K.

Where do these numbers come from?

Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Company data

Denali Therapeutics Inc. employees and revenue per employee

DNLI · Biotechnology · $3.09B market cap

Denali Therapeutics Inc. had 445 employees at the end of fiscal Dec 2023, up 4.2% from a year earlier. Revenue for the year was $331M, up 204.7% from a year earlier, or $743K per employee. Revenue and headcount both grew, and revenue grew faster.

The latest annual report we hold is more than two years old, so these numbers may be out of date.

Employees

445

+4.2% YoY

Revenue

$331M

+204.7% YoY

Revenue / employee

$743K

Peer median $459K

Rank in industry

41 of 109

Biotechnology

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2018

Hover a year for the numbers.

DNLI employees and revenue by fiscal year
Year ending	Employees	Revenue	Per employee	Staff YoY	Revenue YoY
Dec 2023	445	$331M	$743K	+4.2%	+204.7%
Dec 2022	427	$108M	$254K	+12.4%	+122.9%
Dec 2021	380	$48.7M	$128K	+30.6%	-85.5%
Dec 2020	291	$336M	$1.15M	+11.5%	+1158.2%
Dec 2019	261	$26.7M	$102K	+45.8%	-79.3%
Dec 2018	179	$129M	$722K	—	—

Open roles: we have not matched a verified job board for this company yet.

Employees, last six fiscal years

Revenue per employee, last six fiscal years

Denali Therapeutics Inc. against similar companies

The closest industry peers by revenue, from Biotechnology.

Company	Employees	Revenue	Revenue / employee	Shape
RIGL Rigel Pharmaceuticals, Inc.	172	$294M	$1.71M	Efficient growth
CRMD CorMedix Inc.	191	$312M	$1.63M	Efficient growth
KRYS Krystal Biotech, Inc.	295	$389M	$1.32M	Efficient growth
ARQT Arcutis Biotherapeutics, Inc.	354	$376M	$1.06M	Efficient growth
DNLI Denali Therapeutics Inc.	445	$331M	$743K	Efficient growth
VCEL Vericel Corporation	398	$276M	$694K	Efficient growth
XERS Xeris Biopharma Holdings, Inc.	435	$292M	$671K	Efficient growth
ADPT Adaptive Biotechnologies Corporation	624	$277M	$444K	Efficient growth
TWST Twist Bioscience Corporation	979	$377M	$385K	Efficient growth

Every Healthcare company

Questions about Denali Therapeutics Inc.

How many employees does Denali Therapeutics Inc. have?: Denali Therapeutics Inc. reported 445 employees for the fiscal year ending Dec 2023, in the annual report it filed on February 28, 2024. That is up 4.2% from a year earlier.
What is Denali Therapeutics Inc.'s revenue per employee?: Denali Therapeutics Inc. brought in $331M of revenue in fiscal Dec 2023, which is $743K per employee. That ranks 41 of 109 companies we track in Biotechnology, where the median is $459K.
Where do these numbers come from?: Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Free game

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

More data

Compare DNLI with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Leaderboard Healthcare

Source: employee counts and revenue as stated in Denali Therapeutics Inc.'s annual reports (Form 10-K), latest filed February 28, 2024. This is data, not a recommendation to buy or sell DNLI.